Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Immune System Regulator Allows Inflammatory Response While Preventing Autoimmune Attack

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Image: Schematic of balance between tolerance and inflammation mediated by BACH2 (Photo courtesy of the US National Institutes of Health).
Image: Schematic of balance between tolerance and inflammation mediated by BACH2 (Photo courtesy of the US National Institutes of Health).
The BACH2 (BTB and CNC homology 1, basic leucine zipper transcription factor 2) gene was shown recently to encode for a protein that acts as a master immune system regulator by enabling inflammatory response to disease causing agents on the one hand and by preventing a hyper-inflammatory response and autoimmune attack on the other.

Genetic polymorphisms within a single locus encoding the BACH2 transcription factor are associated with numerous autoimmune and allergic diseases including asthma, Crohn’s disease, celiac disease, vitiligo, multiple sclerosis, and type I diabetes. The BACH2 protein is normally found on the surface of CD4+ T-cells. These cells play a dual role within the immune system with some populations of CD4+ T-cells activating immune responses, while others, regulatory T-cells (Tregs), function to limit immune responses. An in-depth study of how the BACH2 regulatory factor controls the balance between the two types of immune response was conducted by investigators at the [US] National Institutes of Health (Bethesda, MD, USA).

The investigators worked with a genetically engineered mouse line that permitted silencing or activation of BACH2. They found that the loss of the BACH2 gene in CD4+ T-cells caused them to become inflammatory, even in situations that would normally result in the formation of protective regulatory cells. Mice lacking the BACH2 gene generated large numbers of inflammatory cells, and the animals died of autoimmune diseases within the first few months of life. Insertion of the BACH2 gene via gene therapy into BACH2-deficient cells restored their ability to produce regulatory cells.

"Although genes have been found that play specific roles in either inflammatory cells or regulatory cells, BACH2 regulates the choice between the two cell types, resulting in its critical role in maintaining the immune system’s healthy balance," said senior author Dr. Nicholas P. Restifo, an investigator at the [US] National Institutes of Health. "It is apt that the gene shares its name with the famous composer Bach, since it orchestrates many components of the immune response, which, like the diverse instruments of an orchestra, must act in unison to achieve symphonic harmony."

The study was published in the June 2, 2013, online edition of the journal Nature.

Related Links:

[US] National Institutes of Health



WATERS CORPORATION

Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

27 May 2015 - 28 May 2015
02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.